Clinical-stage company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need.
Contineum Therapeutics
Neurology
Total Addressable Market
$20 billion+
Red Tree Board Member(s)
Red Tree Participation
Co-investor in Series C